tetano
Editor, Senior Moderator
J Int Med Res
. 2023 Aug;51(8):3000605231193580.
doi: 10.1177/03000605231193580. High-flow nasal cannula therapy in patients with COVID-19 in intensive care units in a country with limited resources: a single-center experience
Anh-Minh Vu Phan[SUP] 1 [/SUP], Hai-Yen Thi Hoang[SUP] 1 [/SUP], Thanh-Son Truong Do[SUP] 1 [/SUP], Trung Quoc Hoang[SUP] 2 [/SUP], Thuan Van Phan[SUP] 2 [/SUP], Nguyet-Anh Phuong Huynh[SUP] 3 [/SUP], Khoi Minh Le[SUP] 2 4 [/SUP]
Affiliations
Objective: This study was performed to determine the outcomes of patients with coronavirus disease 2019 (COVID-19) who developed hypoxemic respiratory failure necessitating high-flow nasal cannula (HFNC) therapy and to identify the predictors of HFNC therapy success.
Methods: This retrospective observational study involved all patients treated with HFNC therapy at a center for COVID-19 in Viet Nam from August to October 2021.
Results: The study recruited 302 patients. Of these 302 patients, 171 (56.6%) underwent successful HFNC therapy, and the all-cause mortality rate was 33.44%. Non-critical COVID-19 and a higher respiratory rate-oxygenation (ROX) index at 48 hours after initiating HFNC therapy were independently correlated with HFNC therapy success. The statistically significant predictors of HFNC therapy success were younger age, non-critical COVID-19, a higher platelet count when starting HFNC therapy, and a higher ROX index at 24, 36, and 48 hours after HFNC therapy initiation.
Conclusions: HFNC therapy appears to be effective in patients with COVID-19 who develop respiratory failure requiring respiratory support. Non-critical COVID-19 and a higher ROX index measured 48 hours after HFNC therapy initiation might serve as predictive factors for the success of HFNC therapy.
Keywords: Acute respiratory distress syndrome; COVID-19; developing country; high-flow nasal cannula; intensive care unit; respiratory rate–oxygenation index.
. 2023 Aug;51(8):3000605231193580.
doi: 10.1177/03000605231193580. High-flow nasal cannula therapy in patients with COVID-19 in intensive care units in a country with limited resources: a single-center experience
Anh-Minh Vu Phan[SUP] 1 [/SUP], Hai-Yen Thi Hoang[SUP] 1 [/SUP], Thanh-Son Truong Do[SUP] 1 [/SUP], Trung Quoc Hoang[SUP] 2 [/SUP], Thuan Van Phan[SUP] 2 [/SUP], Nguyet-Anh Phuong Huynh[SUP] 3 [/SUP], Khoi Minh Le[SUP] 2 4 [/SUP]
Affiliations
- PMID: 37607569
- DOI: 10.1177/03000605231193580
Objective: This study was performed to determine the outcomes of patients with coronavirus disease 2019 (COVID-19) who developed hypoxemic respiratory failure necessitating high-flow nasal cannula (HFNC) therapy and to identify the predictors of HFNC therapy success.
Methods: This retrospective observational study involved all patients treated with HFNC therapy at a center for COVID-19 in Viet Nam from August to October 2021.
Results: The study recruited 302 patients. Of these 302 patients, 171 (56.6%) underwent successful HFNC therapy, and the all-cause mortality rate was 33.44%. Non-critical COVID-19 and a higher respiratory rate-oxygenation (ROX) index at 48 hours after initiating HFNC therapy were independently correlated with HFNC therapy success. The statistically significant predictors of HFNC therapy success were younger age, non-critical COVID-19, a higher platelet count when starting HFNC therapy, and a higher ROX index at 24, 36, and 48 hours after HFNC therapy initiation.
Conclusions: HFNC therapy appears to be effective in patients with COVID-19 who develop respiratory failure requiring respiratory support. Non-critical COVID-19 and a higher ROX index measured 48 hours after HFNC therapy initiation might serve as predictive factors for the success of HFNC therapy.
Keywords: Acute respiratory distress syndrome; COVID-19; developing country; high-flow nasal cannula; intensive care unit; respiratory rate–oxygenation index.